SCHEMBL13627931

SCHEMBL13627931

Cc1ccc(CN2C(=O)/C(=N\O)c3cc(Cl)ccc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.56
CA2 P00918 4/20 0.56
CA12 O43570 3/20 0.56
CA9 Q16790 3/20 0.56
ALDH3A1 P30838 5/20 0.51
ALDH1A1 P00352 3/20 0.51
ALDH2 P05091 1/20 0.51
UCHL3 P15374 3/20 0.50
UCHL1 P09936 3/20 0.50
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
POLB P06746 1/20 0.50
CA4 P22748 1/20 0.48
ACHE P22303 1/20 0.48
HSP90AA1 P07900 1/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627889 0.92 ACHE (0.54) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627874 0.92 ALDH3A1 (0.56) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627921 0.91 ACHE (0.58) CA1CA2CA12CA9ALDH1A1
SCHEMBL13627933 0.88 TP53 (0.53) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627928 0.87 ALDH3A1 (0.51) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627927 0.87 ALDH3A1 (0.68) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627964 0.86 UCHL3 (0.53) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627905 0.86 ACHE (0.60) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627888 0.86 APAF1 (0.60) CA1CA2CA12CA9ALDH3A1
SCHEMBL13627940 0.86 CHRM5 (0.51) CA1CA2CA12CA9ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CA1 3628/4885CA2 3142/4885CA12 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.